These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30294801)

  • 1. RNA-based markers in biopsy cores with atypical small acinar proliferation: Predictive effect of T2E fusion positivity and MMP-2 upregulation for a subsequent prostate cancer diagnosis.
    Eryilmaz IE; Aytac Vuruskan B; Kaygısız O; Egeli U; Tunca B; Kordan Y; Cecener G
    Prostate; 2019 Feb; 79(2):195-205. PubMed ID: 30294801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
    Eryilmaz IE; Kordan Y; Vuruskan BA; Kaygısız O; Tunca B; Cecener G
    Gene; 2018 Mar; 645():69-75. PubMed ID: 29277318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are biomarkers evaluated in biopsy specimens predictive of prostate cancer aggressiveness?
    Carozzi F; Tamburrino L; Bisanzi S; Marchiani S; Paglierani M; Di Lollo S; Crocetti E; Buzzoni C; Burroni E; Greco L; Baldi E; Sani C
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):201-12. PubMed ID: 26210155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
    Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
    Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
    Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical small acinar proliferation suspicious for malignancy in prostate needle biopsies: clinical significance in 33 cases.
    Iczkowski KA; MacLennan GT; Bostwick DG
    Am J Surg Pathol; 1997 Dec; 21(12):1489-95. PubMed ID: 9414193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
    Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
    BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
    Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
    Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
    Berg KD
    Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA
    Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer diagnosed after initial biopsy with atypical small acinar proliferation suspicious for malignancy is similar to cancer found on initial biopsy.
    Iczkowski KA; Chen HM; Yang XJ; Beach RA
    Urology; 2002 Nov; 60(5):851-4. PubMed ID: 12429314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies.
    Scattoni V; Roscigno M; Freschi M; Dehò F; Raber M; Briganti A; Fantini G; Nava L; Montorsi F; Rigatti P
    Arch Ital Urol Androl; 2005 Mar; 77(1):31-6. PubMed ID: 15906787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2-ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer.
    Kron KJ; Murison A; Zhou S; Huang V; Yamaguchi TN; Shiah YJ; Fraser M; van der Kwast T; Boutros PC; Bristow RG; Lupien M
    Nat Genet; 2017 Sep; 49(9):1336-1345. PubMed ID: 28783165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
    Warrick JI; Humphrey PA
    Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
    Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
    JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice patterns of clinicians following isolated diagnoses of atypical small acinar proliferation on prostate biopsy specimens.
    Fadare O; Wang S; Mariappan MR
    Arch Pathol Lab Med; 2004 May; 128(5):557-60. PubMed ID: 15086303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stratification of aggressive prostate cancer from indolent disease-Prospective controlled trial utilizing expression of 11 genes in apparently benign tissue.
    Alinezhad S; Väänänen RM; Tallgrén T; Perez IM; Jambor I; Aronen H; Kähkönen E; Ettala O; Syvänen K; Nees M; Kallajoki M; Taimen P; Boström PJ; Pettersson K
    Urol Oncol; 2016 Jun; 34(6):255.e15-22. PubMed ID: 26857646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How many cores should be taken in a repeat biopsy on patients in whom atypical small acinar proliferation has been identified in an initial transrectal prostate biopsy?
    Aglamis E; Kocaarslan R; Yucetas U; Toktas G; Ceylan C; Doluoglu OG; Unluer E
    Int Braz J Urol; 2014; 40(5):605-12. PubMed ID: 25498271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.